The global market for Overactive Bladder (OAB) Therapeutics was valued at US$ 5354 million in the year 2024 and is projected to reach a revised size of US$ 6306 million by 2031, growing at a CAGR of 2.4% during the forecast period.

Overactive Bladder (OAB) Therapeutics Market

Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Overactive Bladder (OAB) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder (OAB) Therapeutics.

The Overactive Bladder (OAB) Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Overactive Bladder (OAB) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Overactive Bladder (OAB) Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Overactive Bladder (OAB) Therapeutics Market Report

Report Metric	Details
Report Name	Overactive Bladder (OAB) Therapeutics Market
Accounted market size in year	US$ 5354 million
Forecasted market size in 2031	US$ 6306 million
CAGR	2.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Anticholinergic Agents Beta-3 Adrenoreceptor Agonists
Segment by Application	Hosptial Clinci Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Overactive Bladder (OAB) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Overactive Bladder (OAB) Therapeutics Market growing?

Ans: The Overactive Bladder (OAB) Therapeutics Market witnessing a CAGR of 2.4% during the forecast period 2025-2031.

What is the Overactive Bladder (OAB) Therapeutics Market size in 2031?

Ans: The Overactive Bladder (OAB) Therapeutics Market size in 2031 will be US$ 6306 million.

Who are the main players in the Overactive Bladder (OAB) Therapeutics Market report?

Ans: The main players in the Overactive Bladder (OAB) Therapeutics Market are Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries

What are the Application segmentation covered in the Overactive Bladder (OAB) Therapeutics Market report?

Ans: The Applications covered in the Overactive Bladder (OAB) Therapeutics Market report are Hosptial, Clinci, Other

What are the Type segmentation covered in the Overactive Bladder (OAB) Therapeutics Market report?

Ans: The Types covered in the Overactive Bladder (OAB) Therapeutics Market report are Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists

1 Overactive Bladder (OAB) Therapeutics Market Overview

1.1 Product Definition

1.2 Overactive Bladder (OAB) Therapeutics by Type

1.2.1 Global Overactive Bladder (OAB) Therapeutics Market Value Comparison by Type (2024 VS 2031)

1.2.2 Anticholinergic Agents

1.2.3 Beta-3 Adrenoreceptor Agonists

1.3 Overactive Bladder (OAB) Therapeutics by Application

1.3.1 Global Overactive Bladder (OAB) Therapeutics Market Value by Application (2024 VS 2031)

1.3.2 Hosptial

1.3.3 Clinci

1.3.4 Other

1.4 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts

1.4.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2020-2031

1.4.2 Global Overactive Bladder (OAB) Therapeutics Sales 2020-2031

1.4.3 Global Overactive Bladder (OAB) Therapeutics Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers

2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2020-2025)

2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Overactive Bladder (OAB) Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Product Type & Application

2.7 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Date of Enter into This Industry

2.8 Global Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends

2.8.1 Global Overactive Bladder (OAB) Therapeutics Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue

2.8.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Overactive Bladder (OAB) Therapeutics Market Scenario by Region

3.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2020-2031

3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2020-2025

3.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2026-2031

3.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2020-2031

3.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2020-2025

3.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2026-2031

3.4 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country

3.4.1 North America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2031)

3.4.3 North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country

3.5.1 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2031)

3.5.3 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Region

3.6.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2020-2031)

3.6.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country

3.7.1 Latin America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2031)

3.7.3 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country

3.8.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2031)

3.8.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2020-2031)

4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2020-2025)

4.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2026-2031)

4.1.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2020-2031)

4.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2020-2031)

4.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2020-2025)

4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2026-2031)

4.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2020-2031)

4.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2020-2031)

5 Segment by Application

5.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2020-2031)

5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2020-2025)

5.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2026-2031)

5.1.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2020-2031)

5.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2020-2031)

5.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2020-2025)

5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2026-2031)

5.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2020-2031)

5.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Allergan

6.1.1 Allergan Company Information

6.1.2 Allergan Description and Business Overview

6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio

6.1.5 Allergan Recent Developments/Updates

6.2 Astellas Pharma

6.2.1 Astellas Pharma Company Information

6.2.2 Astellas Pharma Description and Business Overview

6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio

6.2.5 Astellas Pharma Recent Developments/Updates

6.3 Hisamitsu Pharmaceutical

6.3.1 Hisamitsu Pharmaceutical Company Information

6.3.2 Hisamitsu Pharmaceutical Description and Business Overview

6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio

6.3.5 Hisamitsu Pharmaceutical Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Ferring

6.5.1 Ferring Company Information

6.5.2 Ferring Description and Business Overview

6.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio

6.5.5 Ferring Recent Developments/Updates

6.6 GlaxoSmithKline

6.6.1 GlaxoSmithKline Company Information

6.6.2 GlaxoSmithKline Description and Business Overview

6.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio

6.6.5 GlaxoSmithKline Recent Developments/Updates

6.7 Ion Channel Innovations

6.7.1 Ion Channel Innovations Company Information

6.7.2 Ion Channel Innovations Description and Business Overview

6.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio

6.7.5 Ion Channel Innovations Recent Developments/Updates

6.8 Kwang Dong Pharmaceutical

6.8.1 Kwang Dong Pharmaceutical Company Information

6.8.2 Kwang Dong Pharmaceutical Description and Business Overview

6.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio

6.8.5 Kwang Dong Pharmaceutical Recent Developments/Updates

6.9 Lanzhou Institute of Biological Products

6.9.1 Lanzhou Institute of Biological Products Company Information

6.9.2 Lanzhou Institute of Biological Products Description and Business Overview

6.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio

6.9.5 Lanzhou Institute of Biological Products Recent Developments/Updates

6.10 Merck

6.10.1 Merck Company Information

6.10.2 Merck Description and Business Overview

6.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio

6.10.5 Merck Recent Developments/Updates

6.11 ONO Pharmaceutical

6.11.1 ONO Pharmaceutical Company Information

6.11.2 ONO Pharmaceutical Description and Business Overview

6.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio

6.11.5 ONO Pharmaceutical Recent Developments/Updates

6.12 Sanofi

6.12.1 Sanofi Company Information

6.12.2 Sanofi Description and Business Overview

6.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio

6.12.5 Sanofi Recent Developments/Updates

6.13 Tengion

6.13.1 Tengion Company Information

6.13.2 Tengion Description and Business Overview

6.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio

6.13.5 Tengion Recent Developments/Updates

6.14 Teva Pharmaceutical Industries

6.14.1 Teva Pharmaceutical Industries Company Information

6.14.2 Teva Pharmaceutical Industries Description and Business Overview

6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio

6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis

7.2 Overactive Bladder (OAB) Therapeutics Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Overactive Bladder (OAB) Therapeutics Production Mode & Process Analysis

7.4 Overactive Bladder (OAB) Therapeutics Sales and Marketing

7.4.1 Overactive Bladder (OAB) Therapeutics Sales Channels

7.4.2 Overactive Bladder (OAB) Therapeutics Distributors

7.5 Overactive Bladder (OAB) Therapeutics Customer Analysis

8 Overactive Bladder (OAB) Therapeutics Market Dynamics

8.1 Overactive Bladder (OAB) Therapeutics Industry Trends

8.2 Overactive Bladder (OAB) Therapeutics Market Drivers

8.3 Overactive Bladder (OAB) Therapeutics Market Challenges

8.4 Overactive Bladder (OAB) Therapeutics Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Hisamitsu Pharmaceutical

Ferring

GlaxoSmithKline PLC

Ion Channel Innovations

Kwang Dong Pharmaceutical

Lanzhou Institute of Biological Products

Teva Pharmaceutical Industries

Astellas Pharma

Allergan plc

Pfizer Inc

List of Tables

Table 1. Global Overactive Bladder (OAB) Therapeutics Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Overactive Bladder (OAB) Therapeutics Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Overactive Bladder (OAB) Therapeutics Market Competitive Situation by Manufacturers in 2024

Table 4. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Overactive Bladder (OAB) Therapeutics Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Overactive Bladder (OAB) Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Product Type & Application

Table 12. Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2020-2025) & (K Units)

Table 18. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2020-2025)

Table 19. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2026-2031) & (K Units)

Table 20. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2026-2031)

Table 21. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2020-2025)

Table 23. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2026-2031)

Table 25. North America Overactive Bladder (OAB) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2025) & (K Units)

Table 27. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2026-2031) & (K Units)

Table 28. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2025) & (K Units)

Table 32. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2026-2031) & (K Units)

Table 33. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) by Type (2020-2025)

Table 51. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) by Type (2026-2031)

Table 52. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2020-2025)

Table 53. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2026-2031)

Table 54. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2020-2025)

Table 57. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2026-2031)

Table 58. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Type (2020-2025)

Table 59. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Type (2026-2031)

Table 60. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) by Application (2020-2025)

Table 61. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) by Application (2026-2031)

Table 62. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2020-2025)

Table 63. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2026-2031)

Table 64. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2020-2025)

Table 67. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2026-2031)

Table 68. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Application (2020-2025)

Table 69. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Application (2026-2031)

Table 70. Allergan Company Information

Table 71. Allergan Description and Business Overview

Table 72. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Allergan Overactive Bladder (OAB) Therapeutics Product

Table 74. Allergan Recent Developments/Updates

Table 75. Astellas Pharma Company Information

Table 76. Astellas Pharma Description and Business Overview

Table 77. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product

Table 79. Astellas Pharma Recent Developments/Updates

Table 80. Hisamitsu Pharmaceutical Company Information

Table 81. Hisamitsu Pharmaceutical Description and Business Overview

Table 82. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product

Table 84. Hisamitsu Pharmaceutical Recent Developments/Updates

Table 85. Pfizer Company Information

Table 86. Pfizer Description and Business Overview

Table 87. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Pfizer Overactive Bladder (OAB) Therapeutics Product

Table 89. Pfizer Recent Developments/Updates

Table 90. Ferring Company Information

Table 91. Ferring Description and Business Overview

Table 92. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Ferring Overactive Bladder (OAB) Therapeutics Product

Table 94. Ferring Recent Developments/Updates

Table 95. GlaxoSmithKline Company Information

Table 96. GlaxoSmithKline Description and Business Overview

Table 97. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product

Table 99. GlaxoSmithKline Recent Developments/Updates

Table 100. Ion Channel Innovations Company Information

Table 101. Ion Channel Innovations Description and Business Overview

Table 102. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product

Table 104. Ion Channel Innovations Recent Developments/Updates

Table 105. Kwang Dong Pharmaceutical Company Information

Table 106. Kwang Dong Pharmaceutical Description and Business Overview

Table 107. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product

Table 109. Kwang Dong Pharmaceutical Recent Developments/Updates

Table 110. Lanzhou Institute of Biological Products Company Information

Table 111. Lanzhou Institute of Biological Products Description and Business Overview

Table 112. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product

Table 114. Lanzhou Institute of Biological Products Recent Developments/Updates

Table 115. Merck Company Information

Table 116. Merck Description and Business Overview

Table 117. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Merck Overactive Bladder (OAB) Therapeutics Product

Table 119. Merck Recent Developments/Updates

Table 120. ONO Pharmaceutical Company Information

Table 121. ONO Pharmaceutical Description and Business Overview

Table 122. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product

Table 124. ONO Pharmaceutical Recent Developments/Updates

Table 125. Sanofi Company Information

Table 126. Sanofi Description and Business Overview

Table 127. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 128. Sanofi Overactive Bladder (OAB) Therapeutics Product

Table 129. Sanofi Recent Developments/Updates

Table 130. Tengion Company Information

Table 131. Tengion Description and Business Overview

Table 132. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 133. Tengion Overactive Bladder (OAB) Therapeutics Product

Table 134. Tengion Recent Developments/Updates

Table 135. Teva Pharmaceutical Industries Company Information

Table 136. Teva Pharmaceutical Industries Description and Business Overview

Table 137. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 138. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product

Table 139. Teva Pharmaceutical Industries Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Overactive Bladder (OAB) Therapeutics Distributors List

Table 143. Overactive Bladder (OAB) Therapeutics Customers List

Table 144. Overactive Bladder (OAB) Therapeutics Market Trends

Table 145. Overactive Bladder (OAB) Therapeutics Market Drivers

Table 146. Overactive Bladder (OAB) Therapeutics Market Challenges

Table 147. Overactive Bladder (OAB) Therapeutics Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Product Picture of Overactive Bladder (OAB) Therapeutics

Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Overactive Bladder (OAB) Therapeutics Market Share by Type: 2024 & 2031

Figure 4. Anticholinergic Agents Product Picture

Figure 5. Beta-3 Adrenoreceptor Agonists Product Picture

Figure 6. Global Overactive Bladder (OAB) Therapeutics Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Overactive Bladder (OAB) Therapeutics Market Share by Application: 2024 & 2031

Figure 8. Hosptial

Figure 9. Clinci

Figure 10. Other

Figure 11. Global Overactive Bladder (OAB) Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Overactive Bladder (OAB) Therapeutics Market Size (2020-2031) & (US$ Million)

Figure 13. Global Overactive Bladder (OAB) Therapeutics Sales (2020-2031) & (K Units)

Figure 14. Global Overactive Bladder (OAB) Therapeutics Average Price (USD/Unit) & (2020-2031)

Figure 15. Overactive Bladder (OAB) Therapeutics Report Years Considered

Figure 16. Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers in 2024

Figure 17. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players: Market Share by Revenue in Overactive Bladder (OAB) Therapeutics in 2024

Figure 19. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2020-2031)

Figure 22. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2020-2031)

Figure 23. U.S. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2020-2031)

Figure 26. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2020-2031)

Figure 27. Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2020-2031)

Figure 34. China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Taiwan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2020-2031)

Figure 45. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. U.A.E Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Overactive Bladder (OAB) Therapeutics by Type (2020-2031)

Figure 55. Global Revenue Market Share of Overactive Bladder (OAB) Therapeutics by Type (2020-2031)

Figure 56. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Overactive Bladder (OAB) Therapeutics by Application (2020-2031)

Figure 58. Global Revenue Market Share of Overactive Bladder (OAB) Therapeutics by Application (2020-2031)

Figure 59. Global Overactive Bladder (OAB) Therapeutics Price (USD/Unit) by Application (2020-2031)

Figure 60. Overactive Bladder (OAB) Therapeutics Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions